Fibrosis occurs in the advanced stages of many organ diseases and cancers. Here, a pathological accumulation of extracellular matrix leads to a thickening and hardening of the organ, which restricts its function. This pathological tissue prevents the appropriate drugs from reaching the affected cells. As a result, there are currently no truly effective anti-fibrotic drugs, making fibrosis a serious medical challenge.
Mamta Chabria is developing specific peptides to counter the matrix that acts as a barrier and accelerates the progression of fibrosis. This will allow drugs to target precisely the right place – meaning greater efficacy and fewer side effects.